Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients. 18. September 2021 Gröschel, A., Passlick, B., Stuschke, M., Christopoulos, P., Reck, M., Grah, C., Growth, A., Hipper, A., Chiabudini, M., Fleitz, A., Jänicke, M., Spring, L., Christoph, D. C., Bernhardt, C., Reiser, M., Zahn, M.-O., Sebastian, M., Griesinger, F., Thomas, M., Eberhardt, W., 2021. Annals of Oncology, Volume 32, Supplement 5, 2021, Pages S935-S936. https://doi.org/10.1016/j.annonc.2021.08.1765. Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315). Griesinger F., Sebastian M., Brückl W., Hummel H.-D., Jaeschke B., Kern J., Wesseler C., Jänicke M., Fleitz A., Zacharias S., Hipper A., Groth A., Weichert… Weiterlesen Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL M. Thill, M.-O. Zahn, A. Welt, E. Stickeler, A. Nusch, T. Fietz, J. Rauh, N. Wetzel, L. Kruggel, M. Jänicke, N. Marschner, N. Harbeck, A. Weiterlesen